Eli Lilly and Company (NYSE:LLY) Shares Sold by Sarasin & Partners LLP

Sarasin & Partners LLP trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 10.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 228,058 shares of the company’s stock after selling 27,437 shares during the period. Eli Lilly and Company makes up about 2.0% of Sarasin & Partners LLP’s portfolio, making the stock its 22nd biggest position. Sarasin & Partners LLP’s holdings in Eli Lilly and Company were worth $188,355,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the business. FPC Investment Advisory Inc. grew its holdings in Eli Lilly and Company by 358.3% during the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock worth $45,000 after acquiring an additional 43 shares during the period. Mascagni Wealth Management Inc. purchased a new stake in Eli Lilly and Company in the 4th quarter worth approximately $43,000. Prudent Man Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $48,000. Compass Financial Services Inc acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $50,000. Finally, Capital A Wealth Management LLC purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at approximately $63,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 4.4%

Shares of LLY opened at $807.75 on Wednesday. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The stock has a market capitalization of $765.54 billion, a price-to-earnings ratio of 68.98, a PEG ratio of 1.40 and a beta of 0.41. The stock has a 50 day moving average price of $770.33 and a 200 day moving average price of $800.86.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same period last year, the firm earned $2.58 EPS. The company’s revenue for the quarter was up 45.2% compared to the same quarter last year. Equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were given a dividend of $1.50 per share. The ex-dividend date was Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.74%. Eli Lilly and Company’s payout ratio is presently 48.82%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Wells Fargo & Company reissued an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Morgan Stanley reissued an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Erste Group Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Thursday, June 5th. The Goldman Sachs Group raised Eli Lilly and Company from a “neutral” rating to a “buy” rating and reduced their price target for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. Finally, UBS Group lowered their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating on the stock in a research report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,011.37.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at $4,778,521.60. This trade represents a 14.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.